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Summary.-l. Successive sampling of ovarian cancers during cytostatic treatment
showed several cases of notable changes in their ploidy distribution and one change
in modal chromosome number, indicating selection of a resistant tumour-cell popu-
lation. 2. Studies of cell suspensions from human tumour specimens incubated with
[3H] -TdR after exposure in vitro to various cytostatic agents have shown variation in
labelling between different parts of the same tumour, as well as between the primary
tumour and its metastases or ascitic tumour-cell population, which may be accounted
for by variation in sensitivity of the tumour-cell population. 3. Studies of nuclear
morphology in20 endometrial cancers before and after progesterone therapy demon-
strate considerable variation in the proportion of cells undergoing secretory con-
version within the same tumour, indicating primary heterogeneity of the tumour-cell
population in response to progesterone.
PERSISTENCE and early recurrence of
human tumours after cytostatic or hor-
monal treatment starts from surviving
cells. Such cells may be less sensitive due
to natural primary resistance to the treat-
ment. This postulates that the tumour-
cell population is heterogeneous for sensi-
tivity to various cytostatic drugs or
hormones.
Cytogenetic and cytochemical studies
have demonstrated that some experi-
mental as well as human tumours are
composed of more than one cell clone,
which often differ significantly in their
biological characteristics (Bishun et al.,
1973; Mian et al., 1974; Mitelman, 1971;
Palyi et al., 1977). Several studies indicate
that this biological heterogeneity of the
tumour-cell population is also expressed
in different sensitivities to various cyto-
static drugs, both in animal and human
tumour-cell lines (Hakansson & Trope,
1974; Trope & Hakansson, 1974; Trope
et al., 1975; Whisson & Siracky, 1969).
There is still the problem of estimating
or characterizing the type and degree of
cellular heterogeneity of human tumours
in respect of their sensitivity to various
therapeutic agents, at the cellular level
and in vtvo.
In the present investigations we have
attempted clinical interpretation of the
problem of cellular heterogeneity in differ-
ent types and sites of human tumours.
MATERIALS AND METHODS
Ploidy in ovarian cancers during cytostatic
treatment.-The study comprised 12 inoper-
able ovarian cancers with primary chemo-
therapy (Leukeran, Burroughs Wellcome,
London;Mannogranol, GedeonRichter, Buda-
pest; TS-160, SPOFA, Prague; Cytembena,
SPOFA, Prague). Before, during and 2-3
days after terminating the cytostatic treat-
ment, repeated chromosomal analyses (at
about 10-day intervals) of cancer cells from
ascitic fluid were performed. The first samples
were taken immediately before cytostatic
treatment.
Within a few minutes of withdrawal,
Colcemid (CIBA, Basel; 2 mg/l) was added to
the ascitic fluid for 2 h at 37°C. Cells were then
treated with hypotonic 1 ,/,, sodium citrate
solution for 30 min and fixed repeatedly in
methanol-acetic acid (1: 3). Air-dried slidesCELL HETEROGENEITY OF HUMAN TUMOURS
were stained with Giemsa solution, metapha-
ses photographed, the chromosomes counted
and summarising histograms produced.
Incorporation of 3H-TdR in tumour-cell
su8pensions after 3 h exposure in vitro to
various cytostatics -If human tumours are
heterogeneous in their sensitivity to cyto-
static drugs, the sensitivity results from small
biopsies in an in vitro test are not likely to be
representative of the whole tumour. To over-
come this problem the following studies were
made:
1. Comparison of different regions, as dis-
tant as possible, of the same tumour (one
ovarian and 2 colon cancers).
2. Comparison of primary tumours with
their metastases and/or comparison of dif-
ferent metastatic nodes of the same patient
(one ovarian cancer, primary tumour and
omentum metastasis; and one ovarian cancer,
different metastatic nodes only).
3. Comparison of primary tumours and
their ascitic tumour-cell populations (one
ovarian and one gastric cancer).
All specimens were obtained at operation.
The tumour material was brought into cell
suspension. The cells were washed in MEM,
resuspended, assayed for cell viability by
Trypan blue, and distributed into test tubes
(107 viable cells in each). The tumour cells
were then incubated in MEM with cytostatic
drugs for 3 h (Alkeran (ALK), Burroughs
Wellcome, London; Ftorafur (FF), Medex,
Moscow; Fluorouracil (FU), Hoffmann-La-
Roche, Basel; Oxauracyl (OXAUR), VUFB,
Prague; Methotrexate (MTX), Lederle, Pearl
River, N.Y.; TS-160, SPOFA, Prague; Vin-
blastine (VINBL), GedeonRichter, Budapest;
Vincristine (VINCR), Gedeon Richter, Buda-
pest). Drug concentrations corresponded to
those used for treatment in man (mg/g body
wt converted to mg/ml medium).
Then 3H-thymidine (3H-TdR 0-025 ml,
0 5 ,tCi/ml, sp.act. 22 Ci/mmol UVVR,
Prague) was added to give a final concentra-
tion of 2 ,Ci/ml and the incubation was con-
tinued for a further hour. Controls without
cytostatics were set up in each series ofexperi-
ments. All tests were performed in duplicate.
3H-TdR incorporation into DNA was deter-
mined by liquid-scintillation counting. The
effect of cytostatic drugs is expressed as a
reduction in ct/min/107 cells in treated cells
relative to the controls.
Nuclear morphology in endometrial cancer
undergoing progesterone treatment.-Twenty
patients with endometrial cancer who were
given progesterone as a preliminary thera-
peutic measure have beeninvestigated.
Tissue samples were obtained at the diag-
nostic curettage (A sample). All patients were
then submitted to progesterone therapy
(DEPO Provera, Upjohn S.A., Puurs, Bel-
gium) i.m. on consecutive days to a total
amount of 600 mg. On the 8th-lOth day after
progesterone therapy, several tissue samples
(B sample) were obtained, either from curet-
tage before intracavitary radium treatment,
or at hysterectomy. All tissue specimens were
fixed in methanol/formalin/acetic-acid mix-
ture for 24 h, embedded in paraffin and 4 ,um
histological section were stained with haema-
toxylin and eosin. In each specimen (A or B)
150-200 tumour-cell nuclei were studied at
random for measurement ofthelong andslhort
axes, the ratio of the 2 axes being ex-
pressed as the "elongation". Secretory con-
version of the endometrial cell population is
morphologically expressed by shortening of
the long axis ofthe nuclei, thus decreasing the
elongation (Epifanova, 1971).
In all these specimens some aspects of cell
kinetics were also studied using double label-
ling wvith 3H-TdR-14C-TdR, the results of
which are published separately (Siracky et al.,
1978).
RESULTS AND DISCUSSION
Ploidy
All the cases in our series were charac-
terized before treatment by a wide range
of ploidy, with modal chromosome num-
bers in the diploid or hyperdiploid range,
which is characteristic of ascites tumour
cell populations in ovarian cancer (Atkin,
1976; Koller, 1972).
"Number ofmitoses studied" in Table I
refers to samples studied before, during
and after cytostatic treatment in
sequence. Some of the cases are repre-
sented by only 2 samples (before and after
treatment) due to inhibition of the ascites
proliferation. "Modal chromosome num-
ber" refers to the pretreatment sample,
and apart from case No. 11 (Fig. 2) no
changes in modal chromosome number
during cytostatic treatment were de-
tected. In several of these cases, however,
distinct changes in ploidy distribution
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FIG. 1. Ploidy distribution before (I) (luring
(II, III) and after (IV) cytostatic treatment
of tumour No. 7 in Table I.
(cases 1, 3, 5, 7 and 12) during cytostatic
treatment were evident. This type of
chromosomal change seems to demon-
strate selective overgrowth of cell clones,
those resistant to the cytostatic treatment
(Fig. 1 clearly demonstrates this type of
change).
One spontaneous change with the age
of the ascites is polyploidization (Koller,
1972) which is also to be expected as the
result of damage to the mitotic process of
cells by alkylating agents (Bishun, 1971;
Nasjleti & Spencer, 1967). The ploidy
distribution changes in our series are,
however, characterized by decrease and/or
disappearance of polyploid cells, which
suggests increased sensitivity of polyploid
clones to cytostatic drugs.
This form of sequential cytogenetic
study during the follow-up of a patient
(Eicke et al., 1965; Mohr et al., 1966;
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Fie. 2. Modal chromosome number before
(I), during (II, III, IV) and after (V) cyto-
static treatment of tumour No. 11 in
Table 1.
Siracky, 1969; Visfeldt & Lundwall, 1970)
illustrates biological and cytogenetically
expressed heterogeneity ofthe tumour-cell
population in sensitivity to cytostatic
agents, and contributes to a better under-
standing of the processes of cell selection
in human tumours during treatment.
There are, however, great difficulties in
the interpretation of such analyses, since
most of the cases with effusions are in an
advanced stage, with metastatic dissemi-
nation and very poor prognosis.
3H-TdR incorporation
In most of the investigated cases,
different parts of the same tumour,
different metastatic nodes of the same
patient, as well as the primary tumour and
its ascitic form, differ significantly in their
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TABLE I1.-Differences in drug sensitivity of samplesfrom different areas within the same
tumour (expressed as ct/min/107 cells after uptake of [3H]-TdR)
Ca colon
FU
ct/min %
MTX
ct/min %
289 93-5 90
256 66-6 80
312 74*1 487
FU
ct/min %
312 105-4
230 71-4
FU
ct/min %
403 88-2
305 76-8
400 76-3
TS
ct/min %
29-1 77
20-8 44
115.7 95
MTX
ct/min %
270 91-2
292 90 7
MTX
ct/min %
312 68-2
370 93-2
305 58-2
VINCR
ct/min %
24-9 212
114 52
22-6 7
TS
ct/min %
250 84-5
174 54-0
68*6
13*5
1*6
VINBL
ct/min %
222 75 0
76 23*6
TS
ct/min %
125 27-3
231 58-2
96 18*3
Dose schedule in Tables II, III and IV:
ALK- 0-2 mg/ml
FF- 2-0 mg/ml
FU- 0 5 mg/ml
MTX- 0.05 mg/ml
OXAUR-0.01 mg/ml
TS- 0-1 mg/ml
VINBL- 0-1 mg/ml
VINCR- 0 1 mg/ml
TABLE III.-Differences in drug sensitivity of samples from primary tumours and their
metastases and/or between different metastatic nodes (Expressed as ct/min/107 cells after
quptake of [3H]-TdR)
Advanced Ca ovary with metastatic dissemirnation
Prir
tv
Control
Sample ct/min %
nary 1 704 100
amour 2 652 100
TS
ct/min
368 52-2
310 47-5
MTX
ct/min m
693 98-4
699 107-2
FU
ct/min m
480 68-2
334 51*2
Metastatic
node 786 100 249 31-7 522 66-4 449 57-1
Advanced Ca ovary-metastases omenti maioris
Control
ct/min %
801 100
661 100
604 100
TS
ct/min
165 20-6
157 23-7
251 41-6
MTX
ct/min %
1110 138-6
367 55-5
970 160*6
FU
ct/min %
553 69-0
221 33-4
377 62-4
sensitivity to the same cytostatic treat-
ment in vitro (Tables II, III, IV). These
variations in tissue specimens might be
explained by local nutritional conditions,
by variations in the proliferation rate and/
or by variations in the amount of necrosis
in different parts of the tumour. These
factors ought to be responsible for differ-
ences in the incorporation of the 3H-TdR
in control specimens, but no large differ-
ences were found between controls. It can
be assumed, therefore, that the differences
in sensitivity to cytostatic treatment are
due to the presence of 2 or more clones
of tumour cells differing in their biological
characteristics.
Control
ct/min %
309
384
421
100
100
100
Sample
1
2
3
Ca sigmae
Sample
1
2
Ca ovary
Sample
1
2
3
Control
ct/min %
296 100
322 100
Control
ct/min %
457 100
397 100
524 100
Sample
Met. 1
Met. 2
Met. 3
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TABLE IV.-Differences in drug sensitivity of primary tumours and their ascitic tumour-
cellpopulation (expressed as ct/min/107 cells after uptake of [3H]-TdR)
Advanced gastric cancer with ascites
Control ALK
Sample ct/mirm % ct/min %
Tumour 399 100 432 108-2
Ascites 474 100 198 41.7
Advanced Ca ovary with ascites
Control FU
Sample ct/min % ct/min %
Tumour 378 100 371 92 2
Ascites 459 100 670 146.0
FU
ct/min %
213 53*4
144 30-3
MTX
ct/min %
668 176*7
295 64-2
MTX
Ct/min %
195 48 9
96 20*3
TS
ct/min %O
211 558
236 51*4
FF
ct/min %
384 96*2
108 22*8
OXAUR
ct/min %
309 81.8
228 49.7
N clear morphology
Clinical experience has shown that endo-
metrial cancers are hormone (progester-
one) responsive in a considerable percent-
age of cases (Kelley & Baker, 1965; Smith
et al., 1966). Several studies have also
demonstrated secretory conversion, mostly
in highly differentiated cancers, manifest-
ing itself by characteristic changes in
TABLE V.-% of cells from 20 endometrial
cancers with mean length of nucleus
<12 pm, before and after progesterone
treatment
No.
1
2t
3
4
5
6
7
8
9
10
11
12
13
14*
15
16*
17
18*
19*
20*
Degree of
differentiation
H
H
H
H
H
H
H
M
M
M
M
M
M
M
M
M
p
p
p
p
Before
treatment
58 3
45.7
54-6
68 1
58*7
53.5
60-0
56-4
58 6
55.5
57.3
53.9
58-9
46*9
44.3
48*6
38-4
43 2
48 8
44.9
After
treatment
85-0
842
73 6
84-0
83-1
81-7
84-1
66-8
63-4
62-9
78 0
62-4
87-8
54 1
55.1
56-9
54-8
52-0
53-1
51-4
* Separation into 2 distinct cell populations as
seen in Fig. 4.
t See Fig. 3.
H =high. M =Moderate. P =Poor.
12 ,um was selected as the mean +s.d. for pre-
treatment samples.
nuclear morphology as a result of pro-
gesterone treatment (Hustin, 1976; Mar-
tinez-Manaton et al., 1975). Secretory
conversion implies loss of proliferative
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FIG. 3. Secretory conversion (as indicated
by change in nuclear shape) of the tumour
cells in a highlv differentiated cancer (No. 2
in Table V). A=before and B=after pro-
gesterone treatment.
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FIG. 4.-Separation of 2 distinct tumour-
cell populations in their response to pro-
gesterone in a case of poorly differentiated
cancer (No. 19 in Table V). A=before and
B =after treatment.
capacity and might be a prelethal stage
(Epifanova, 1971).
Most ofthe highly differentiated cancers
in our series exhibited significant re-
sponses to progesterone, expressed as
rising values of potential doubling time
in post-treatment specimens (Siracky et
al., 1978) as well as showing secretory con-
version of a significant fraction of the
tumour-cell population (Table V, Fig. 3).
In highly differentiated cancers of our
series the ratio of long-short axis ofnuclei
changed from 1*74 + 052 before to 1-35 +
0-41 after progesterone treatment. The
mean length of the long axis was 10X38 +
2X34 ,m before and 8X69 + 2X03 ,m after
treatment.
Examples of the changes in nuclear
morphology after progesterone treatment
are showninFigs 3 and 4. Table Vpresents
the changes in percentage of nuclei
<12 pm long in 20 different endometrial
tumours.
In the group of moderately and poorly
differentiated cancers, in spite of nearly
unchanged values both in proliferation
kinetics and nuclear morphology after
progesterone treatment, a distinct fraction
of the tumour-cell population undergoing
secretory conversion could be detected by
plotting the nuclear morphology para-
meters innomograms (Fig. 4) which clearly
demonstrated differences in response to
progesterone treatment within the cell
population of a single tumour. It appears,
however, that recognition of 2 different
types of cell population, as seen in
Fig. 4B, would be possible only in tumours
with about equal amounts of both cell
types.
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